Clinical Documentation for 70-Year-Old Female with Worsening Renal Function
History of Present Illness
This patient requires immediate nephrology referral and urgent dialysis evaluation given eGFR 24 mL/min/1.73 m² (Stage 4 CKD progressing toward Stage 5), rising BUN and creatinine, and intentional severe fluid restriction causing pre-renal azotemia superimposed on chronic kidney disease. 1
Chief Complaint
Progressive worsening of renal function with rising BUN (46 mg/dL) and creatinine (2.2 mg/dL), declining eGFR (24 mL/min/1.73 m²) over 2-week period following recent hospitalization for AKI with hyperkalemia.
Present Illness Details
- Recent hospitalization: AKI with hyperkalemia (now corrected)
- Current laboratory trends 2:
- BUN: 31 → 33 → 46 mg/dL (progressive elevation)
- Creatinine: 1.6 → 1.8 → 2.2 mg/dL (37% increase from baseline)
- eGFR: 35 → 30 → 24 mL/min/1.73 m² (31% decline, now Stage 4 CKD)
- Sodium and potassium: within normal limits
- Critical behavioral factor: Patient intentionally restricts fluid intake to avoid urination, creating pre-renal component
- Symptom status: Denies uremic symptoms (nausea, vomiting, pruritus, altered mental status, dyspnea)
- Medication review needed: Assess for nephrotoxic agents (NSAIDs), ACE inhibitors/ARBs (may cause reversible GFR decline), diuretics 3, 4
Review of Systems
Constitutional
- Fatigue or weakness (uremic symptoms) 1
- Unintentional weight changes
- Fever or chills (infection risk)
Cardiovascular
- Chest pain or palpitations (hyperkalemia risk, though currently normal K+) 2
- Orthopnea or paroxysmal nocturnal dyspnea (volume overload) 4
- Lower extremity edema 4
Respiratory
- Dyspnea at rest or with exertion (metabolic acidosis, volume overload) 1
- Cough (pulmonary edema)
Gastrointestinal
- Nausea, vomiting, anorexia (uremic symptoms) 1
- Diarrhea or constipation
- Abdominal pain
Genitourinary
- Urine output volume and frequency (oliguria indicates worsening kidney function) 5
- Dysuria, hematuria
- Nocturia patterns
Neurological
- Confusion, altered mental status (uremic encephalopathy) 1
- Seizures
- Peripheral neuropathy symptoms
Musculoskeletal
Integumentary
- Pruritus (uremia) 1
- Easy bruising (uremic platelet dysfunction)
Physical Examination
Vital Signs
- Blood pressure (assess for hypertension vs. hypotension from volume depletion) 6, 7
- Heart rate and rhythm (arrhythmia risk with electrolyte shifts) 2
- Respiratory rate (Kussmaul respirations suggest metabolic acidosis) 1
- Temperature (infection)
- Weight (compare to recent hospitalization for volume status) 4
- Oxygen saturation
General Appearance
- Level of alertness and orientation (uremic encephalopathy) 1
- Signs of distress or uremic appearance
Cardiovascular
- Jugular venous pressure (volume status assessment) 4
- Heart sounds (pericardial friction rub indicates uremic pericarditis) 1
- Peripheral pulses
- Capillary refill
Respiratory
- Lung auscultation for crackles (volume overload) or clear fields 4
- Work of breathing
Abdominal
- Distension, tenderness
- Bowel sounds
- Organomegaly
Extremities
- Edema (pitting vs. non-pitting, location, severity) 4
- Skin turgor and mucous membrane moisture (volume depletion from fluid restriction) 5
- Asterixis (uremic encephalopathy) 1
Skin
Neurological
- Mental status examination
- Focal deficits
- Reflexes
Assessment
Primary Diagnosis
Acute-on-chronic kidney disease (Stage 4 CKD, eGFR 24 mL/min/1.73 m²) with pre-renal azotemia secondary to intentional severe fluid restriction, in a patient with hypertension, type 2 diabetes mellitus, and recent AKI with hyperkalemia. 8, 5
Supporting Evidence
- Progressive renal dysfunction: 37% creatinine increase and 31% eGFR decline over 2 weeks indicates acute component 5
- Pre-renal component: BUN:Cr ratio >20:1 (46:2.2 = 20.9) with intentional fluid restriction 5
- Stage 4 CKD: eGFR 24 mL/min/1.73 m² places patient at high risk for progression to Stage 5 (kidney failure) 6, 1
- Diabetes and hypertension: Major risk factors for CKD progression 6, 7
Differential Considerations
- Medication-induced AKI (ACE inhibitors, ARBs, NSAIDs, diuretics) 3, 4
- Contrast-induced nephropathy (if recent imaging)
- Urinary obstruction (requires imaging)
- Rapidly progressive glomerulonephritis (less likely without hematuria/proteinuria)
- Atheroembolic disease
Complications to Monitor
- Electrolyte abnormalities (hyperkalemia recurrence, hypocalcemia, hyperphosphatemia, hypomagnesemia) 9, 2, 10
- Metabolic acidosis 4, 1
- Volume overload vs. dehydration 4
- Anemia of CKD 4
- Metabolic bone disease 4
- Uremic complications (pericarditis, encephalopathy, bleeding) 1
Detailed Management Plan
Immediate Actions (Within 24 Hours)
1. Urgent Nephrology Referral
Immediate nephrology consultation is mandatory given eGFR <30 mL/min/1.73 m² and rapid decline, with preparation for potential kidney replacement therapy. 6, 7, 1
- eGFR 24 mL/min/1.73 m² is approaching absolute indication for RRT planning (eGFR <15) 1
- Risk of kidney failure within 1 year exceeds 20% threshold for timely referral 1
- Nephrology will assess need for urgent vs. elective dialysis initiation 1
2. Comprehensive Laboratory Assessment
Obtain complete metabolic panel, arterial blood gas, complete blood count, phosphate, magnesium, calcium, parathyroid hormone, and urinalysis with microscopy within 6 hours. 9, 4, 2, 10
Critical laboratory monitoring 2:
- Electrolytes every 6-12 hours initially given recent hyperkalemia and Stage 4 CKD 2
- Serum potassium (target 4.0-5.0 mmol/L to prevent cardiac arrhythmias) 2
- Sodium, chloride, bicarbonate (assess for metabolic acidosis) 4, 1
- Phosphate (hyperphosphatemia common in CKD) 4, 10
- Magnesium (hypomagnesemia in 12% of hospitalized patients) 9, 10
- Calcium (hypocalcemia in CKD) 4, 10
- Complete blood count (anemia of CKD) 4
- Arterial blood gas if bicarbonate <22 mEq/L (metabolic acidosis assessment) 1
- Parathyroid hormone and 25-hydroxyvitamin D (metabolic bone disease) 4
Urinalysis with microscopy 8, 5:
- Assess for proteinuria, hematuria, casts
- Urine albumin-to-creatinine ratio (UACR) 6, 7, 4
- Spot urine sodium and creatinine (calculate fractional excretion of sodium to confirm pre-renal etiology)
3. Medication Reconciliation and Adjustment
Immediately review and adjust all medications for eGFR 24 mL/min/1.73 m², discontinue nephrotoxins, and assess ACE inhibitor/ARB dosing. 6, 7, 4, 1
ACE inhibitor/ARB management 6, 7, 4:
- Continue ACE inhibitor or ARB even with eGFR <30 mL/min/1.73 m² unless creatinine rose >30% within 4 weeks of initiation 6, 7
- Check serum creatinine and potassium 2-4 weeks after any dose adjustment 6, 7
- Small elevations in creatinine (up to 30%) with RASi are expected and renoprotective, not true AKI 4
- Consider dose reduction only if symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or to reduce uremic symptoms 6, 7
- NSAIDs (nephrotoxic, increase hyperkalemia risk) 4, 1
- Potassium-sparing diuretics if hyperkalemia recurs 2, 1
- Metformin if eGFR <30 mL/min/1.73 m² (lactic acidosis risk)
- All medications requiring renal dose adjustment 1
Avoid 4:
- Iodinated contrast (contrast-induced nephropathy risk) 4
- Aminoglycosides and other nephrotoxic antibiotics
4. SGLT2 Inhibitor Consideration
Initiate SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) given type 2 diabetes and eGFR ≥20 mL/min/1.73 m². 6, 7
- Strong 1A recommendation for patients with T2D, CKD, and eGFR ≥20 mL/min/1.73 m² 6, 7
- Continue even if eGFR falls below 20 unless not tolerated or KRT initiated 6, 7
- Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 6, 7
- Does not require alteration of CKD monitoring frequency 6, 7
- Reversible eGFR decrease on initiation is not indication to discontinue 6, 7
5. Fluid Management Strategy
Implement structured hydration protocol with goal of 1.5-2 liters daily oral fluid intake, with patient education on importance of adequate hydration to prevent pre-renal azotemia. 5, 1
Rationale:
- Current intentional fluid restriction is causing pre-renal component (BUN:Cr ratio >20:1) 5
- Adequate hydration essential to prevent further AKI 5
- Avoid aggressive IV fluids given Stage 4 CKD and volume overload risk 1
- If IV fluids needed, use balanced crystalloids rather than 0.9% saline 1
Patient education 5:
- Explain that adequate fluid intake will not worsen kidney function
- Discuss strategies to manage urinary frequency (timed voiding, pelvic floor exercises)
- Consider urology referral if overactive bladder symptoms present
Short-Term Management (1-7 Days)
6. Hyperkalemia Prevention and Monitoring
Implement hyperkalemia prevention protocol with dietary potassium restriction (2-3 g/day), medication review, and frequent potassium monitoring every 6-12 hours initially. 2, 11, 12, 13
- Restrict dietary potassium to 2-3 g/day (2000-3000 mg/day)
- Avoid high-potassium foods (bananas, oranges, tomatoes, potatoes, salt substitutes)
- Dietitian consultation for renal diet education
Monitoring strategy 2:
- Serum potassium every 6-12 hours for first 48 hours 2
- Then daily until stable
- Obtain ECG immediately if potassium >6.0 mmol/L 2
- Target potassium 4.0-5.0 mmol/L 2
Rule out pseudohyperkalemia 2:
- Repeat measurement with proper technique if elevated
- Avoid repeated fist clenching during phlebotomy 2
- Consider arterial sample if hemolysis suspected 2
Risk factors present 11:
- eGFR <45 mL/min/1.73 m² (patient has eGFR 24) 11
- Diabetes mellitus 11
- Likely on ACE inhibitor or ARB 11
If hyperkalemia recurs 12, 13, 14:
- Consider newer potassium binders (patiromer or sodium zirconium cyclosilicate) to allow continuation of RASi therapy 12, 14
- Avoid discontinuing ACE inhibitor/ARB if possible, as this increases mortality 12, 14
7. Metabolic Acidosis Management
Monitor for metabolic acidosis with serum bicarbonate and arterial blood gas; treat if bicarbonate <22 mEq/L with oral sodium bicarbonate 650-1300 mg three times daily. 4, 1
- Metabolic acidosis common in Stage 4-5 CKD 4
- Check serum bicarbonate and anion gap 1
- If bicarbonate <22 mEq/L, initiate oral sodium bicarbonate 4
- Monitor for volume overload with sodium bicarbonate therapy 4
8. Anemia Assessment and Management
Check hemoglobin, iron studies (serum iron, TIBC, ferritin, transferrin saturation); initiate erythropoiesis-stimulating agent if hemoglobin <10 g/dL and iron replete. 4
- Anemia of CKD expected with eGFR <30 mL/min/1.73 m² 4
- Iron deficiency common; supplement if ferritin <100 ng/mL or transferrin saturation <20% 4
- Target hemoglobin 10-11.5 g/dL (avoid >13 g/dL due to cardiovascular risk) 4
9. Mineral Bone Disease Evaluation
Assess calcium, phosphate, parathyroid hormone, and 25-hydroxyvitamin D; initiate phosphate binders if phosphate >5.5 mg/dL and vitamin D supplementation if deficient. 4
- Metabolic bone disease common in CKD 4
- Check PTH, calcium, phosphate, vitamin D 4
- Restrict dietary phosphate to 800-1000 mg/day 4
- Initiate phosphate binders with meals if hyperphosphatemia present 4
- Supplement vitamin D if 25(OH)D <30 ng/mL 4
10. Blood Pressure Management
Target blood pressure <130/80 mmHg using ACE inhibitor or ARB as first-line agent, with addition of other antihypertensives as needed. 6, 7, 4
- Hypertension accelerates CKD progression 3, 6, 7
- Continue ACE inhibitor or ARB for renoprotection 6, 7
- Add calcium channel blocker or diuretic if needed for BP control 6, 7
- Monitor BP at every visit 4
Medium-Term Management (1-4 Weeks)
11. Renal Replacement Therapy Planning
Initiate comprehensive RRT education covering hemodialysis, peritoneal dialysis, kidney transplantation, and conservative management options. 1
Patient and family education 1:
- Hemodialysis (in-center vs. home)
- Peritoneal dialysis (continuous ambulatory vs. automated)
- Kidney transplantation (living vs. deceased donor)
- Conservative management (supportive care without dialysis)
Vascular access planning 1:
- Refer to vascular surgery for arteriovenous fistula creation if hemodialysis anticipated
- Fistula requires 3-6 months to mature before use
- Avoid venipuncture and blood pressure measurements in non-dominant arm (preserve veins)
Peritoneal dialysis catheter 1:
- Consider if patient prefers home-based therapy
- Requires abdominal surgery for catheter placement
Transplant evaluation 1:
- Refer to transplant center if candidate
- Living donor evaluation if available
12. Nutritional Management
Refer to renal dietitian for comprehensive dietary counseling on protein restriction (0.8 g/kg/day), potassium restriction (2-3 g/day), phosphate restriction (800-1000 mg/day), and sodium restriction (<2 g/day). 4, 10
Dietary recommendations 4, 10:
- Protein: 0.8 g/kg/day (avoid excessive restriction to prevent malnutrition)
- Potassium: 2-3 g/day (2000-3000 mg/day)
- Phosphate: 800-1000 mg/day
- Sodium: <2 g/day (2000 mg/day)
- Fluid: 1.5-2 liters/day (adjust based on urine output and volume status)
- Calories: adequate to maintain body weight
Micronutrient supplementation 9:
- Water-soluble vitamins (B-complex, vitamin C, folate) often deficient in CKD 9
- Avoid vitamin A supplementation (accumulates in kidney failure)
- Monitor and supplement thiamine, vitamin B6, folate 9
13. Diabetes Management
Optimize glycemic control with target HbA1c <7% using renal-dosed medications; discontinue metformin given eGFR <30 mL/min/1.73 m². 4
- Adjust all diabetes medications for eGFR 24 mL/min/1.73 m² 4
- Discontinue metformin (lactic acidosis risk with eGFR <30) 4
- SGLT2 inhibitor appropriate (see above) 6, 7
- Insulin often required in advanced CKD (reduced clearance, adjust doses)
- Monitor glucose every 4-6 hours if hospitalized 9
14. Cardiovascular Risk Reduction
Initiate statin therapy for cardiovascular risk reduction and optimize management of hypertension and diabetes. 6, 7, 4
- CKD is cardiovascular disease equivalent 6, 7
- Statin therapy reduces cardiovascular events in CKD 6, 7
- Aspirin for secondary prevention if indicated
- Smoking cessation counseling if applicable
Long-Term Management (>1 Month)
15. Ongoing Monitoring Schedule
Establish regular follow-up schedule with nephrology every 2-4 weeks initially, then monthly once stable, with laboratory monitoring every 1-3 months. 4, 5
Laboratory monitoring frequency 4:
- Stage 4 CKD: every 3-5 months when stable 4
- More frequent (every 1-3 months) given recent AKI and rapid decline 4
- Electrolytes, BUN, creatinine, eGFR 4
- Calcium, phosphate, PTH, vitamin D 4
- Hemoglobin, iron studies 4
- Urinalysis and UACR 4
Clinical monitoring 4:
- Blood pressure at every visit 4
- Weight and volume status 4
- Medication review and adjustment 4
- Assessment for uremic symptoms 1
- Evaluation for CKD complications 4
16. Advance Care Planning
Initiate advance care planning discussions regarding goals of care, dialysis preferences, and end-of-life wishes. 1
- Discuss prognosis and expected disease trajectory
- Document advance directives
- Identify healthcare proxy
- Discuss quality of life priorities
- Consider palliative care consultation if conservative management preferred
Critical Pitfalls to Avoid
Do not delay nephrology consultation waiting for further deterioration; urgent dialysis may be needed if hyperkalemia worsens, acidosis progresses, or uremic symptoms develop. 1
Avoid discontinuing ACE inhibitor/ARB solely due to eGFR <30 mL/min/1.73 m² or small creatinine increases (<30%); these medications provide critical renoprotection and cardiovascular benefit. 6, 7, 4
Do not aggressively administer IV fluids given Stage 4 CKD and volume overload risk; use balanced crystalloids rather than 0.9% saline if IV fluids needed. 1
Pseudohyperkalemia must always be ruled out before aggressive treatment by repeating measurement with proper technique or obtaining arterial sample. 2
Review all medications that can cause hyperkalemia (RASi, potassium-sparing diuretics, NSAIDs, beta-blockers, trimethoprim-sulfamethoxazole, heparin, calcineurin inhibitors) and discontinue or dose-adjust as necessary. 2, 1
All nephrotoxic medications should be discontinued or dose-adjusted for eGFR <30 mL/min/1.73 m². 1
Avoid venipuncture and blood pressure measurements in non-dominant arm to preserve veins for future vascular access. 1
Do not wait until eGFR <15 mL/min/1.73 m² to initiate RRT planning; vascular access creation requires 3-6 months for fistula maturation. 1